The clinical value of circulating cell free DNA in multiple myeloma

Abstract Purpose: To evaluate the feasibility of the detection of circulating cell free DNA (cfDNA) and the prognostic value of cfDNA in patients with multiple myeloma (MM).Experimental design: All samples were screened hematopoietic malignancy associated genetic mutations from cfDNA and bone marrow (BM), using the Next-generation sequencing (NGS). The mutated genetic, checked in both cfDNA and BM, were monitered at the different time points during the treatment by droplet-based digital PCR (ddPCR).Results: Three patients were included in our prospective study. Two patients detected DNMT3A mutations and one patient detected GNAQ mutation. The abundance of mutations decreased as the disease remission, and increased as the disease progresses. The detection of cfDNA has shown to predict relapses before paraprotein.Conclusions: cfDNA is a sensitive tool for monitoring compared to paraprotein levels. The utility of cfDNA for monitoring disease is Promising.